Dialysis-dependent renal failure in patients with multiple myeloma: Reversibility factors
- Authors: Rekhtina IG1, Mendeleeva LP1, Biryukova LS1
-
Affiliations:
- «Гематологический научный центр» Минздрава России
- Issue: Vol 87, No 7 (2015)
- Pages: 72-76
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31783
- ID: 31783
Cite item
Full Text
Abstract
Aim. To establish the reversibility factors of dialysis-dependent renal failure (RF) in patients with multiple myeloma (MM) treated according to bortezomib-containing programs. Subjects and methods. The efficiency of treatment according to bortezomib-containing programs was evaluated in 40 patients with first diagnosed MM and dialysis-dependent RF. Prior to treatment, 34 patients underwent needle renal biopsy. The early mortality rate was 5%. Results. After treatment according to bortezomib-containing programs, 83% of the patients could achieve a hematologic response, including 66% who had complete and very good partial remission (CR and vgPR). A renal response (RenR) was observed in only 26% of the patients. RenR to antitumor therapy was found to be determined by the morphological variant of nephropathy. Improved kidney function was observed only in cast nephropathy (CN) and absent in other types of kidney injury. In CN, the rate of RenR depends on the degree of renal tubulointerstitial fibrosis at the initiation of treatment. Kidney function improved in 20% of the patients with disseminated tubulointerstitial fibrosis and in 57% of those with minimal fibrotic changes (p=0.04). To achieve RenR, it is important to have an early antitumor response in addition to baseline morphological changes in the nephrobiopsy specimen. When the number of monoclonal light chains (LC) in urine was reduced to 100 mg/day after 2 cycles of induction therapy, RenR was 55%; with a lower antitumor response it was as high as 28% (p=0.04). A LC decrease to the values of vgPR after 2 cycles of induction therapy was noted in only 32% of the patients; 44% of the patients achieved vgPR or CR after an average of 6 (3—13) therapy cycles. Conclusion. In MM patients with dialysis-dependent RF, RenR was caused by the morphological variant of kidney injury and by the degree of tubulointerstitial fibrosis at the therapy initiation, as well as by the rate at which monoclonal LCs reduced.
Keywords
About the authors
I G Rekhtina
«Гематологический научный центр» Минздрава РоссииМосква, Россия
L P Mendeleeva
«Гематологический научный центр» Минздрава РоссииМосква, Россия
L S Biryukova
«Гематологический научный центр» Минздрава РоссииМосква, Россия
References
- Аlexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med. 1990; 150:1693-1695.
- Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Prog. 2003;78:21-33.
- Рехтина И.Г., Бирюкова Л.С., Савченко В.Г. Химиотерапия больных множественной миеломой, осложненной тяжелой почечной недостаточностью. Гематология и трансфузиология. 2010;6:9-13.
- Pichette V, Quérin S, Desmeules M, Ethier J, Copleston P. Renal function recovery in end-stage renal disease. Am J Kidney Dis. 1993;22:398-402.
- Blade J, Fernandez-Llama P, Bosch F, Montolíu J, Lens X, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;17:1889-1893.
- Lee CK, Zangari M, Barlogie B, Fassas A, Rhee F, Thertulien R, Talamo G, Muwalla F, Anaissie E, Hollmig K, Tricotet G. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004;8:823-828.
- Martín Reyes G, Valera A, Frutos MA, Ramos B, Ordóñez V, López de Novales E. Survival of myeloma patients treated with dialysis. Nefrologia. 2003;2:131-136.
- Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K, Kohli HS. Renal involvement in multiple myeloma: a 10-year study. Ren Fal. 2000;4:465-477.
- Murphy PT, Baldeo C, O’Kelly P, Sargant J, Thornton P, McCloy M, Conlon P, Magee C, Denton M, Quinn J. Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma. Br J Haematol. 2014;165(6):890-891.
- Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;3:175-181.
- Pandit SR, Vesole DH. Management of renal dysfunction in multiple myeloma. Curr Treat Options Oncol. 2003;4:239-246.
- Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Grapsa I, Psimenou E, Gika D, Terpos E, Dimopoulos M. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res. 2010;34:1395-1397.
- Рехтина И.Г., Рыжко В.В., Чавынчак Р.Б., Бирюкова Л.С. Проблемы лечения и выживаемость больных множественной миеломой на программном гемодиализе. Терапевтический архив. 2007;8:9-13.
- Менделеева Л.П., Вотякова О.М., Покровская О.С., Рехтина И.Г., Бессмельцев С.С., Голубева М.Е., Дарская Е.И., Загоскина Т.П., Зинина Е.Е., Капланов К.Д., Константинова Т.С., Крючкова И.В., Медведева Н.В., Моторин С.В., Поспелова Т.И., Рыжко В.В., Самойлова О.С., Урнова Е.С., Савченко В.Г. Национальные клинические рекомендации по диагностике и лечению множественной миеломы. Гематология и трансфузиология. 2014; 1(приложение 3):1-24.
- Morabito F, Gentile M, Ciolli S, Petrucci M, Galimberti S, Mele G, Casulli A, Mannina D, Piro E, Pinotti G, Palmieri S, Catalano L, Callea V, Offidani M, Musto P, Bringhen S, Baldini L, Tosi P, Raimondo F, Boccadoro M, Palumbo A, Cavo M. Safety and efficacy of bortezomib- based regimes for multiple myeloma patients with renal impairment: A retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol. 2010;84:223-228.
- Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, Hulin C, Benboubker L, Fuzibet JG, Renaud M, Moreau P, Avet- Loiseau H. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM Phase II Study. Haematologica. 2006;91:1498-1505.
- Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N. Light chain- induced acute renal failure can be reversed by bortezomib-doxorubicin- dexamethasone in multiple myeloma: results of a phase II Study. J Clin Oncology. 2010;30: 4635-4641.
- Molby L, Hansen HH, Jensen EL. Development and treatment of renal insufficiency in multiple myeloma. Ugeskr Laeger. 1994;156: 4343-4347.
- Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473.
- Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo R L, Sezer O, Palumbo A, Harousseau J L, Richardson P G, Barlogie B, Anderson K C, Sonneveld P, Tosi P, Cavo M, Rajkumar V, Durie B GM, San Miguel J. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncology. 2010;33:4976-4984.
- Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant. 2008;23:2052- 2057.
- Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, Ronco P, Brouet JC, Fermand JP. High dose chemotherapy in light chain or heavy chain deposition disease. Kidney Int. 2004;65(2): 642-648.
- Basnayake K, Cheung CK, Sheaff M, Fuggle W, Kamel D, Nakoinz S, Hutchison CA, Cook M, Stoves J, Bradwell AR, Cockwell P. Differential progression of renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. J Clin Pathol. 2010;63:884-887.
- Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, Hattersley J, Evans ND, Chappel MJ, Sampson P, Foggensteiner L, Adu D, Cockwell P. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009;4:745-754.
- Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S, Rajkumar SV, Kyle RA, Leung N. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22:1129-1136.
![](/img/style/loading.gif)